ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.

Administration

Legal

United States

San Francisco, CA, USA

South San Francisco, CA, USA

ORIC Pharmaceuticals

Correlation Ventures

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Welcome!

Thank you for joining Correlation Ventures Network!

To help us best support you in your search, please take a few minutes to tell us about what you are looking for in your next role. We’ll use this information to connect you to relevant opportunities in the Correlation Ventures network as they come up.

You can always update this information later.

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a Correlation Ventures company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Companies you’ll love to work for